MDT

Medtronic
D

MDT

Arincen70/100B

Medtronic stock buybacks 1990–2027

Medtronic spent 267.00M USD buying back its shares in Q1 FY2027, the three months to 31 July 2026, up 117.1% on the same quarter a year before. Medtronic spent 1.18B USD buying back its shares over the last twelve months, up 36.1% on the twelve months before. In fiscal year 2026 it spent 1.04B USD, down 68.0% on the year before.

Last updated 6 Nov 2026 · Next report 24 Nov 2026

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM31 Jul 20261.18B+36.14%3.65B6.13B
FY202624 Apr 20261.04B-68.01%3.64B5.43B
FY202525 Apr 20253.24B+51.31%3.59B5.19B
FY202426 Apr 20242.14B+231.47%3.67B5.20B
FY202328 Apr 2023645.00M-74.65%3.62B4.58B
FY202229 Apr 20222.54B+290.18%3.38B5.98B
FY202130 Apr 2021652.00M-50.83%3.12B4.89B
FY202030 Apr 20201.33B-53.91%2.89B6.02B
FY201926 Apr 20192.88B+32.52%2.69B5.87B
FY201827 Apr 20182.17B-38.74%2.49B3.62B
FY201728 Apr 20173.54B+25.23%2.38B5.63B
FY201629 Apr 20162.83B+47.40%2.14B4.17B
FY201530 Apr 20151.92B-24.79%1.34B4.33B
FY201425 Apr 20142.55B+104.73%1.12B4.56B
FY201330 Apr 20131.25B-13.40%1.06B4.43B
FY201230 Apr 20121.44B+26.32%1.02B3.94B
FY201130 Apr 20111.14B+10.68%969.00M3.19B
FY201030 Apr 20101.03B+35.70%907.00M3.50B
FY200930 Apr 2009759.00M-50.84%843.00M3.22B
FY200830 Apr 20081.54B+48.60%565.00M2.88B
FY200730 Apr 20071.04B-77.72%504.00M2.29B
FY200630 Apr 20064.66B+812.64%464.80M963.20M
FY200530 Apr 2005511.00M-41.96%404.90M2.37B
FY200430 Apr 2004880.50M+110.39%351.50M2.42B
FY200330 Apr 2003418.50M+1,534.77%304.20M1.70B
FY200230 Apr 200225.60M—278.80M1.20B
FY200130 Apr 20010.00-100.00%240.70M1.39B
FY200030 Apr 2000497.40M+31.87%189.50M699.90M
FY199930 Apr 1999377.20M+124.26%131.90M-788.50M
FY199830 Apr 1998168.20M-64.71%102.90M544.90M
FY199730 Apr 1997476.60M+1,318.45%90.70M273.40M
FY199630 Apr 199633.60M-43.15%60.40M336.70M
FY199530 Apr 199559.10M+10.67%47.20M290.30M
FY199430 Apr 199453.40M-62.63%39.00M296.10M
FY199330 Apr 1993142.90M+273.11%33.30M214.40M
FY199230 Apr 199238.30M+732.61%29.30M74.20M
FY199130 Apr 19914.60M-87.73%23.80M60.80M
FY199030 Apr 199037.50M—18.90M51.50M

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about Medtronic's buybacks

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.